Rain Oncology Inc. Common Stock
RAIN
RAIN was delisted on the 25th of January, 2024.
40 hedge funds and large institutions have $77.7M invested in Rain Oncology Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 15 reducing their positions, and 19 closing their positions.
3% more capital invested
Capital invested by funds: $75.1M → $77.7M (+$2.62M)
18% less funds holding
Funds holding: 49 → 40 (-9)
37% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 19
67% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.14M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$1.08M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$329K |
| 4 |
E
Ergoteles
New York
|
+$243K |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.27M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$680K |
| 3 |
State Street
Boston,
Massachusetts
|
-$578K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$499K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$421K |
RAIN Hedge Fund Activity: Q2 2022 in Review
40 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Rain Oncology Inc. Common Stock (RAIN) for Q2 2022, worth a combined $77.7M — up 3.5% from $75.1M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of RAIN and 12 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 5 added.
The largest buyer was UBS O'Connor, opening a new position worth an estimated $1.14M. The largest seller was BlackRock, cutting an estimated $2.27M.
- 40 institutional investors held Rain Oncology Inc. Common Stock (RAIN) as of Q2 2022, down from 49 in Q1 2022.
- Funds reported $77.7M of Rain Oncology Inc. Common Stock stock for Q2 2022, up 3.5% quarter-over-quarter.
- 12 funds opened new Rain Oncology Inc. Common Stock positions in Q2 2022 and 19 closed out, a net change of -7 holders.
- The largest Rain Oncology Inc. Common Stock buyer in Q2 2022 was UBS O'Connor, an estimated $1.14M added.
- The largest Rain Oncology Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $2.27M sold.
Based on aggregated 13F filings for Q2 2022.